CDK4/6 inhibitors as a novel therapeutic approach to treat estrogen receptor (ER) ‐positive breast cancer

  • سال انتشار: 1397
  • محل انتشار: نخستین همایش جامع بین المللی علوم پزشکی، داروسازی و پرستاری
  • کد COI اختصاصی: MPNI01_015
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 606
دانلود فایل این مقاله

نویسندگان

Afarin Aghajari

School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Mohammad Amin Dehghani

Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Fatemeh Dehghani

Department of Genetics, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Jeiran Haghighi

School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

چکیده

Background and aim: One of the most common characteristics of various cancers is the cell cycle dysregulation. Impaired cyclin D-CDK4/6-Rb pathway has been frequently reported in the ER- positive breast cancers, typically associated with endocrine resistance. Among which the cyclin-dependent kinases (CDK) 4/6 inhibitors together with endocrine therapy have been useful in managing the ER+ metastatic breast cancer. The CDK4/6 is an important target in treating the types of cancer, especially in breast cancer, owing to effectively regulation of the cell cycle. Accordingly, one of the advancements in the therapeutic strategies against the breast oncology is oral highly selective CDK inhibitors, including palbociclib, ribociclib, and abemaciclib.Materials and methods: The present study was conducted by the search strategy on PubMed database in English using the keywords, including ER positive breast cancers, CDK4/6 inhibitors, resistance and therapeutic strategies.Results: The improved clinically treatment of hormone receptor-positive breast cancer has been recently reported by the small-molecule CDK4/6 inhibitors, promising success in other malignancies. The mentioned three anticancer drugs have attracted further attention owing to free survival progression on phase III trials and the most common side effects related to grade 3 treatment, including neutropenia, fatigue, nausea and diarrhea. There is no evidence on predictive biomarkers of response to CDK4/6 inhibitors, with the exception of estrogen receptor positivity. The mechanisms of achieving resistance to the CDK4 / 6 inhibitors appear to detect the CDK4/6 inhibitor-mediated therapeutic strategies.Conclusion: Based on the results, multi-omic methods are suggested to find a wide range of targets corresponding to cellular mechanisms for various applications in clinical purposes.

کلیدواژه ها

ER positive breast cancers, CDK4/6 inhibitors, drug resistance, therapeutic strategies.

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.